Enlivex Ltd. (ENLV)
Develops cell therapy that reprograms immune cells to treat arthritis and sepsis.
$2.24-0.47%Healthcare
StockGlow Score
Bearish
BearishBullish
1 year ago-89.7%
The outlook
Enlivex trades near the bottom of its 52-week range and below its major moving averages, reflecting weak recent price momentum. Analyst coverage is sparse with a very low stockGlow score of 19/100, though the average price target sits far above the current price—a gap that likely reflects thin liquidity and speculative positioning rather than fundamental strength.
What’s behind the score
Price trendBelow its 50- & 200-day averages
52-week range1% of the way from its 52-week low to high
Price targetAvg target +13293% vs current price
Market cap
$37.7M
52-wk high
$31.50
52-wk low
$2.08
50-day avg
$8.81
200-day avg
$13.31
Trailing P/E
0.0